Fanconi syndrome due to deferasirox.
Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox.
Rafat
Cédric
C
Université Paris Descartes, Hôpital Necker, APHP, Paris, France.
Fakhouri
Fadi
F
Ribeil
Jean-Antoine
JA
Delarue
Richard
R
Le Quintrec
Moglie
M
D000368:Aged; D001565:Benzoates / Q000009:adverse effects*; D000077588:Deferasirox; D005198:Fanconi Syndrome / Q000139:chemically induced*; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D008297:Male; D014230:Triazoles / Q000009:adverse effects*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox